Enrichment of plasma-derived extracellular vesicles from astrocytes

Enrichment of plasma-derived extracellular vesicles from astrocytes Extracellular vesicles (EVs) are nanoparticles that are secreted by all cells in the body. EVs carries multiple cellular components, such as genetic material, proteins and lipid metabolites that often reflect the content of their cell of origin. They are involved in a wide range of functions by acting … Read more

The Alzheimer’s Association has awarded 3 competitive projects to our unit

Memory Unit Photo 2022

The Alzheimer’s Association has awarded 3 competitive projects to our unit. The funded projects have been the following:   Role of synaptic miRNA and astrocyte miRNA delivery in Alzheimer’s disease (AARG-22-974373) led by Dr Olivia Belvin Alzheimer’s disease (AD) may be driven by a perturbance of small molecules (microRNAs) at neuronal junctions in the brain … Read more

Myelin loss in C9orf72 hexanucleotide expansion carriers

Myelin loss in C9orf72 hexanucleotide expansion carriers   The expansion of the intronic GGGGCC repeat (G4C2) in the C9orf72 gene is the most common genetic cause of Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS) and in the continuum of FTD/ALS. Three pathological mechanisms associated with the presence of this genetic alteration have been described: a … Read more

The Trial Ready Cohort-Down Syndrome (TRC-DS) begins

TRC-DS

A pioneering international study that accelerates the inclusion of adults with Down Syndrome in clinical trials is starting at the Alzheimer-Down Unit of the Hospital de Sant Pau and the Fundació Catalana de Síndome de Down in Barcelona. The Trial Ready Cohort-Down Syndrome (TRC-DS), a new international study funded by the US National Institutes of … Read more

Concordance between amyloid markers in CSF

Delaby Sant Pau Memory Unit - Barcelona

Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is considered a marker of amyloid pathology, a series of studies have shown that a decrease in CSF Aβ1-42 … Read more

Structural changes in the brain of patients with Alzheimer’s begin 20 years before the symptoms onset

Microestructura Alzheimer - Sant Pau Memory Unit - Barcelona

Structural brain changes in Alzheimer’s disease Brain alterations in Alzheimer’s disease patients begin years before symptoms appear and a clinical diagnosis can be made. The neuroimaging team in our group has developed a technique that measures the movement of water particles in the cerebral cortex and makes it possible to detect structural changes in the … Read more